Maximum quantity allowed is 999
请选择数量
CAS RN: 53179-13-8 | 产品编码: P1871
Pirfenidone
×
![]()
×
| 产品编码 | P1871 |
| 纯度/分析方法 | >98.0%(GC) |
| 分子式/分子量 | C__1__2H__1__1NO = 185.23 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 室温 (15°C以下阴凉干燥处) |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 53179-13-8 |
| Reaxys-RN | 1526549 |
| PubChem物质ID | 125307545 |
| MDL编号 | MFCD00866047 |
技术规格
| Appearance | White to Light yellow to Green powder to crystal |
| Purity(GC) | min. 98.0 % |
| Melting point | 107.0 to 111.0 °C |
物性（参考值）
| 熔点 | 109 °C |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H302 : Harmful if swallowed. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相关法规
| RTECS# | UV1148200 |
运输信息
| HS编码* | 2933.39-000 |
应用
Pirfenidone: A Unique Antifibrotic and Anti-Inflammatory Agent
References
- 1)The first reports of pirfenidone as an anti-inflammatory agent
- a)S. M. Gadekar, U.S. Patent 3839346, 1974.
- b)S. M. Gadekar, U.S. Patent 3974281, 1976.
- c)S. M. Gadekar, Jpn. Kokai Tokkyo Koho S49-87677, 1974.
- d)S. M. Gadekar, Jpn. Kokai Tokkyo Koho S51-128437, 1976.
- 2)Unique anti-inflammatory properties of pirfenidone
- 3)The first reports of pirfenidone as an antifibrotic agent
- a)H. Suga, S. Teraoka, K. Ota, S. Komemushi, S. Furutani, S. Yamauchi, S. B. Margolin, Exp. Toxic. Pathol. 1995, 47, 287
- b)S. N. Iyer, J. S. Wild, M. J. Schiedt, D. M. Hyde, S. B. Margolin, S. N. Giri, J. Lab. Clin. Med. 1995, 125, 779.
- c)J. P. Kehrera, S. B. Margolin, Toxicol. Lett. 1997, 90, 125.
- a)H. Suga, S. Teraoka, K. Ota, S. Komemushi, S. Furutani, S. Yamauchi, S. B. Margolin, Exp. Toxic. Pathol. 1995, 47, 287
- 4)The antifibrotic activity of pirfenidone in various organs
- a)S. N. Iyer, G. Gurujeyalakshmi, S. N. Giri, J. Pharmacol. Exp. Ther. 1999, 291, 367.
- b)G. Miric, C. Dallemagne, Z. Endre, S. Margolin, S. M. Taylor, L. Brown, Br. J. Pharmacol. 2001, 133, 687.
- c)H. Oku, T. Shimizu, T. Kawabata, M. Nagira, I. Hikita, A. Ueyama, S. Matsushima, M. Torii, A. Arimura, Eur. J. Pharmacol. 2008, 590, 400.
- d)C. J. Schaefer, D. W. Ruhrmund, L. Pan, S. D. Seiwert, K. Kossen, Eur. Respir. Rev. 2011, 20, 85.
- e)K. Hisatomi, H. Mukae, N. Sakamoto, Y. Ishimatsu, T. Kakugawa, S. Hara, H. Fujita, S. Nakamichi, H. Oku, Y. Urata, H. Kubota, K. Nagata, S. Kohno, BMC Pulm. Med. 2012, 12, 24.
- 5)Reviews
- a) Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib
- B. A. Karimi-Shah, B. A. Chowdhury, N. Engl. J. Med. 2015, 372, 1189.
- b) Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis
- E. S. Kim, G. M. Keating, Drugs 2015, 75, 219.
参考文献
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。